SCHEMBL239725

SCHEMBL239725

CC(C)Cn1c(=O)c2[nH]cnc2n(C)c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 2/20 1.00
PDE4A P27815 8/20 0.79
PDE4B Q07343 8/20 0.79
PDE4C Q08493 8/20 0.79
PDE4D Q08499 8/20 0.79
PDE2A O00408 2/20 0.79
PDE1A P54750 2/20 0.79
PDE1B Q01064 2/20 0.79
PDE1C Q14123 2/20 0.79
ADORA1 P30542 2/20 0.79
CYP1A2 P05177 2/20 0.79
PDE5A O76074 1/20 0.79
CYP3A4 P08684 1/20 0.79
TSHR P16473 1/20 0.79
MAPK1 P28482 1/20 0.79
SCN1A P35498 1/20 0.79
PDE6C P51160 1/20 0.79
PDE3B Q13370 1/20 0.79
PDE7A Q13946 1/20 0.79
PDE3A Q14432 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isobutylmethylxanthine SCHEMBL4262798 0.90 PDE4A (0.92) CFTRPDE4APDE4BPDE4CPDE4D
Isobutylmethylxanthine SCHEMBL50315 0.88 PDE4A (1.00) CFTRPDE4APDE4BPDE4CPDE4D
Isobutylmethylxanthine SCHEMBL28814716 0.88 PDE4A (1.00) CFTRPDE4APDE4BPDE4CPDE4D
SCHEMBL28468033 0.87 CFTR (0.77) CFTRPDE4APDE4BPDE4CPDE4D
Isobutylmethylxanthine SCHEMBL7637581 0.86 PDE4A (0.94) CFTRPDE4APDE4BPDE4CPDE4D
Isobutylmethylxanthine SCHEMBL3185038 0.86 PDE4A (0.83) CFTRPDE4APDE4BPDE4CPDE4D
SCHEMBL27598085 0.85 PDE4A (0.75) CFTRPDE4APDE4BPDE4CPDE4D
SCHEMBL27324979 0.83 CFTR (0.71) CFTRPDE4APDE4BPDE4CPDE4D
SCHEMBL7016029 0.83 ADORA2A (1.00) CFTRPDE4APDE4BPDE4CPDE4D
SCHEMBL9430480 0.83 CFTR (0.71) CFTRPDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0669973-A1 BIOLOGICAL FACTORS AND NEURAL STEM CELLS NEUROSPHERES HOLDINGS LTD. (CA) 1995-09-06 EP claimed
WO-1994010292-A1 BIOLOGICAL FACTORS AND NEURAL STEM CELLS NEUROSPHERES LTD. (CA) 1994-05-11 WO claimed
EP-4747374-A2 ANTISENSE OLIGONUCLEOTIDES AND ARTIFICIAL EXPRESSION CONSTRUCTS FOR EXPRESSING RNA IN INHIBITORY NEURONS Allen Institute (US) 2026-05-27 EP disclosed
WO-2026102237-A1 ARTIFICIAL EXPRESSION CONSTRUCTS FOR MODULATING GENE EXPRESSION IN ASTROCYTES FOR THE ASSESSMENT AND/OR TREATMENT OF EPILEPTIC DISORDERS Allen Institute (US) 2026-05-15 WO disclosed
US-20260071160-A1 SCALABLE BIOREACTOR SYSTEMS AND METHODS FOR TISSUE ENGINEERING FairCraft SAS (FR) 2026-03-12 US disclosed
EP-4689077-A2 CONDITIONALLY IMMORTALIZED STEM CELLS AND USES THEREOF Pluristyx, Inc. (US) 2026-02-11 EP disclosed
US-12467064-B2 Artificial expression constructs for selectively modulating gene expression in interneurons Allen Institute (US) 2025-11-11 US disclosed
US-20250235550-A1 ARTIFICIAL EXPRESSION CONSTRUCTS FOR MODULATING GENE EXPRESSION IN THE CEREBELLUM AND A SECONDARY CELL TYPE Allen Institute (US) 2025-07-24 US disclosed
US-20250236886-A1 ARTIFICIAL EXPRESSION CONSTRUCTS FOR SELECTIVELY MODULATING GENE EXPRESSION IN EXCITATORY CORTICAL NEURONS Allen Institute (US) 2025-07-24 US disclosed
US-20250223612-A1 ARTIFICIAL EXPRESSION CONSTRUCTS FOR SELECTIVELY MODULATING GENE EXPRESSION IN INTERNEURONS Allen Institute (US) 2025-07-10 US disclosed
US-20250188421-A1 METHODS OF MAKING INDUCED PLURIPOTENT STEM CELLS PLURISTYX, INC. (US) 2025-06-12 US disclosed
US-5851832-A In vitro growth and proliferation of multipotent neural stem cells and their progeny NEUROSPHERES, LTD. (CA) 1998-12-22 US disclosed
WO-1998022127-A9 PRETREATMENT WITH GROWTH FACTORS TO PROTECT AGAINST CNS DAMAGE 1998-09-11 WO disclosed
WO-1998022127-A1 PRETREATMENT WITH GROWTH FACTORS TO PROTECT AGAINST CNS DAMAGE NEUROSPHERES HOLDINGS LTD. (CA) 1998-05-28 WO disclosed
US-5750376-A In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny NEUROSPHERES HOLDINGS LTD. (CA) 1998-05-12 US disclosed
EP-0669973-A1 BIOLOGICAL FACTORS AND NEURAL STEM CELLS NEUROSPHERES HOLDINGS LTD. (CA) 1995-09-06 EP disclosed
WO-1994010292-A1 BIOLOGICAL FACTORS AND NEURAL STEM CELLS NEUROSPHERES LTD. (CA) 1994-05-11 WO disclosed
US-5196315-A HUMAN NEURONAL CELL LINE THE JOHNS HOPKINS UNIVERSITY (US) 1993-03-23 US disclosed
EP-0528954-A1 HUMAN NEURONAL CELL LINE THE JOHNS HOPKINS UNIVERSITY (US) 1993-03-03 EP disclosed
WO-1991017242-A1 HUMAN NEURONAL CELL LINE THE JOHNS HOPKINS UNIVERSITY (US) 1991-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260071160-A1 SCALABLE BIOREACTOR SYSTEMS AND METHODS FOR TISSUE ENGINEERING FGF2, FGF23, FIBP CFTR 2192/4885PDE4A 1588/4885PDE4B 2150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.